These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17187291)

  • 1. Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.
    Happe S; Tings T; Koch W; Welsch J; Helmschmied K; Baier PC; Meller J; Wuttke W; Paulus W; Tatsch K; Trenkwalder C
    J Neural Transm (Vienna); 2007; 114(5):589-94. PubMed ID: 17187291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease.
    Spiegel J; Hellwig D; Samnick S; Jost W; Möllers MO; Fassbender K; Kirsch CM; Dillmann U
    J Neural Transm (Vienna); 2007 Mar; 114(3):331-5. PubMed ID: 16715205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of dopamine on response inhibition in Parkinson's disease relates to age-dependent patterns of nigrostriatal degeneration.
    Kübler D; Schroll H; Hamker FH; Joutsa J; Buchert R; Kühn AA
    Parkinsonism Relat Disord; 2019 Jun; 63():185-190. PubMed ID: 30765262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
    Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
    J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease.
    Happe S; Baier PC; Helmschmied K; Meller J; Tatsch K; Paulus W
    J Neurol; 2007 Aug; 254(8):1037-43. PubMed ID: 17351722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease.
    Lokkegaard A; Werdelin LM; Regeur L; Karlsborg M; Jensen SR; Brødsgaard E; Madsen FF; Lonsdale MN; Friberg L
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):508-16. PubMed ID: 17096096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers.
    Ceravolo R; Antonini A; Volterrani D; Rossi C; Goldwurm S; Di Maria E; Kiferle L; Bonuccelli U; Murri L
    Neurology; 2005 Dec; 65(12):1971-3. PubMed ID: 16380622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease.
    Alvarez-Fischer D; Blessmann G; Trosowski C; Béhé M; Schurrat T; Hartmann A; Behr TM; Oertel WH; Höglinger GU; Höffken H
    Neuroimage; 2007 Oct; 38(1):5-12. PubMed ID: 17716921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.
    Navalpotro-Gomez I; Dacosta-Aguayo R; Molinet-Dronda F; Martin-Bastida A; Botas-Peñin A; Jimenez-Urbieta H; Delgado-Alvarado M; Gago B; Quiroga-Varela A; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2065-2076. PubMed ID: 31273436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors associated with the rate of progression of nigrostriatal degeneration in Parkinson's disease.
    Yoo HS; Kim HK; Lee HS; Yoon SH; Na HK; Kang SW; Lee JH; Ryu YH; Lyoo CH
    J Neurol; 2024 Aug; 271(8):5213-5222. PubMed ID: 38839638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
    Rossi C; Genovesi D; Marzullo P; Giorgetti A; Filidei E; Corsini GU; Bonuccelli U; Ceravolo R
    Clin Neuropharmacol; 2017; 40(1):34-36. PubMed ID: 27941527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome.
    Kessler KR; Hamscho N; Morales B; Menzel C; Barrero F; Vives F; Gispert S; Auburger G
    J Neural Transm (Vienna); 2005 Oct; 112(10):1345-53. PubMed ID: 15785866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
    Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
    Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease.
    Siderowf A; Newberg A; Chou KL; Lloyd M; Colcher A; Hurtig HI; Stern MB; Doty RL; Mozley PD; Wintering N; Duda JE; Weintraub D; Moberg PJ
    Neurology; 2005 May; 64(10):1716-20. PubMed ID: 15911797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.